A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaMaria Domenica Cappellini, Antonio Piga, Antonis Kattamis et al.|New England Journal of Medicine|2020Cited by 320
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) TransfusionsMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|Blood|2018Cited by 14
Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe TrialAlì Taher, Maria Domenica Cappellini, Vip Viprakasit et al.|Blood|2020Cited by 8
S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDYMaria Domenica Cappellini, Vip Viprakasit, Alì Taher et al.|HemaSphere|2022Cited by 6
Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) TransfusionsVip Viprakasit, Maria Domenica Cappellini, Alì Taher et al.|Blood|2019Cited by 3